What is Envveno Medical Corporation's earnings per share (EPS)?

Envveno Medical Corporation (NVNO) reported diluted earnings per share of -$33.06 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Envveno Medical Corporation Financials

NVNO

FY2025 annual

Revenue Not reported for FY2025

Net Income -$19.5M +10.8% YoY

EPS (Diluted) -$33.06 YoY not available

Free Cash Flow -$15.6M +7.7% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

This page shows Envveno Medical Corporation (NVNO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NVNO FY2025 2026-08-26

Pre-revenue development spending is being funded mainly through operating cash consumption and investing inflows, not debt.

In FY2025, the net loss of -$19.5M exceeded operating cash outflow of -$15.6M, so accounting losses translated into cash use at roughly 80.0% rather than one-for-one. The improvement from FY2024 was therefore not purely operational: investing cash flow supplied $15.9M in FY2025, far more than the $1.3M inflow a year earlier.

FY2025 spending was split almost evenly between research and development at $10.0M and selling, general, and administrative costs at $10.9M, indicating a development-stage model carrying substantial corporate overhead alongside product investment. The operating loss narrowed to -$20.9M, but the cost base still consumed cash because there was no reported revenue.

Total assets contracted 34.2% from FY2024 while total liabilities remained just $2.4M, indicating balance-sheet shrinkage without a corresponding buildup of debt. The current ratio fell to 13.6x from 20.9x, yet short-term obligations remain small relative to current assets.

Financial Health Signals

Financial health score not available

Envveno Medical Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Envveno Medical Corporation passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Envveno Medical Corporation reported a net loss of $19.5M while operations used $15.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$20.8M

YoY+12.2%

Envveno Medical Corporation's EBITDA was -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.2% from the prior year.

Net Income

-$19.5M

YoY+10.8%

Envveno Medical Corporation reported -$19.5M in net income in fiscal year 2025. This represents an increase of 10.8% from the prior year.

EPS (Diluted)

-$33.06

Envveno Medical Corporation earned -$33.06 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$15.6M

YoY+7.7%

Envveno Medical Corporation recorded an outflow of $15.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 7.7% from the prior year.

Cash & Debt

$3.1M

YoY+74.7%

5Y CAGR-20.0%

Envveno Medical Corporation held $3.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

655,521

Envveno Medical Corporation had 655,521 shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-71.8%

YoY-20.0pp

5Y CAGR+56.9pp

Envveno Medical Corporation's ROE was -71.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.0 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$10.0M

YoY-18.5%

5Y CAGR+18.6%

Envveno Medical Corporation invested $10.0M in research and development in fiscal year 2025. This represents a decrease of 18.5% from the prior year.

Capital Expenditures

$5K

YoY-86.5%

5Y CAGR-51.2%

Envveno Medical Corporation invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 86.5% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

NVNO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NVNO quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$31K-83.3%	$187K-55.8%	$422K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$420K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$187K+7508.2%	$2K
R&D Expenses	N/A	$10.0M-18.5%	$12.2M-9.8%	$13.6M+37.0%	$9.9M+73.1%	$5.7M+34.7%	$4.3M+92.7%	$2.2M+78.1%	$1.2M+90.7%	$650K
SG&A Expenses	N/A	$10.9M-5.7%	$11.6M-0.7%	$11.7M-22.4%	$15.0M+34.5%	$11.2M+128.7%	$4.9M-0.6%	$4.9M-24.2%	$6.5M+18.8%	$5.5M
Operating Income	N/A	-$20.9M+12.3%	-$23.8M+5.6%	-$25.2M-1.2%	-$24.9M-47.6%	-$16.9M-84.9%	-$9.1M-19.0%	-$7.7M+2.3%	-$7.9M-28.7%	-$6.1M
Interest Expense	N/A	N/A	N/A	N/A	$161K+747.4%	$19K+408.2%	$4K+107.5%	-$50K-116.3%	$305K+76.8%	$173K
Net Income	N/A	-$19.5M+10.8%	-$21.8M+7.2%	-$23.5M+4.7%	-$24.7M-49.3%	-$16.5M-80.9%	-$9.1M-19.8%	-$7.6M+41.5%	-$13.0M-67.4%	-$7.8M
EPS (Diluted)	—	-$33.06	-$44.53	-$1.91+13.2%	-$2.20	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$2.1M-1.7%	$2.1M	N/A	$2.6M-10.6%	$2.9M+13.1%	$2.6M	N/A	$2.9M
SG&A Expenses	$1.7M-11.8%	$2.0M	N/A	$2.3M-44.7%	$4.2M+73.5%	$2.4M	N/A	$3.3M
Operating Income	-$3.8M+6.5%	-$4.1M	N/A	-$4.9M+30.7%	-$7.0M-42.3%	-$5.0M	N/A	-$6.2M
Net Income	-$3.6M+6.5%	-$3.8M	N/A	-$4.5M+32.2%	-$6.7M-48.7%	-$4.5M	N/A	-$5.6M
EPS (Diluted)	-$5.37+8.8%	-$5.89+81.8%	-$32.28	-$0.23	-$11.52-48.6%	-$7.75-2483.3%	-$0.30+14.3%	-$0.35

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

NVNO Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NVNO quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$29.6M-34.2%	$45.0M-7.6%	$48.6M+16.7%	$41.7M-27.8%	$57.7M+447.5%	$10.5M+206.8%	$3.4M-3.5%	$3.6M+60.7%	$2.2M
Current Assets	$28.8M-34.1%	$43.7M-6.8%	$46.9M+19.0%	$39.4M-28.4%	$55.0M+475.2%	$9.6M+572.0%	$1.4M-49.8%	$2.8M+1564.8%	$170K
Cash & Equivalents	$3.1M+74.7%	$1.8M-51.5%	$3.6M-20.5%	$4.6M-91.7%	$54.7M+486.3%	$9.3M+614.1%	$1.3M-52.3%	$2.7M+3427.8%	$78K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$32K-9.0%	$35K
Total Liabilities	$2.4M-13.0%	$2.8M+14.8%	$2.4M-17.0%	$2.9M-11.0%	$3.3M-4.2%	$3.4M+40.7%	$2.4M+60.5%	$1.5M-88.6%	$13.3M
Current Liabilities	$2.1M+1.3%	$2.1M+52.8%	$1.4M-10.4%	$1.5M-3.2%	$1.6M-50.4%	$3.2M+69.8%	$1.9M+23.2%	$1.5M	N/A
Total Equity	$27.1M-35.6%	$42.2M-8.7%	$46.2M+19.3%	$38.7M-28.8%	$54.4M+666.5%	$7.1M+617.0%	$990K-51.4%	$2.0M+118.3%	-$11.1M
Retained Earnings	-$171.3M-12.8%	-$151.9M-16.8%	-$130.0M-22.1%	-$106.5M-30.1%	-$81.9M-25.3%	-$65.3M-16.3%	-$56.2M-15.7%	-$48.6M-36.7%	-$35.5M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$22.7M-13.2%	$26.1M-11.7%	$29.6M-8.6%	$32.4M-11.6%	$36.6M-9.9%	$40.6M-9.7%	$45.0M-10.8%	$50.4M
Current Assets	$22.1M-13.4%	$25.5M-11.6%	$28.8M-8.5%	$31.5M-11.5%	$35.6M-9.8%	$39.5M-9.7%	$43.7M-10.8%	$49.1M
Cash & Equivalents	$2.8M+9.4%	$2.6M-15.3%	$3.1M+98.5%	$1.5M-24.5%	$2.0M-30.4%	$2.9M+67.4%	$1.8M-90.2%	$17.9M
Total Liabilities	$2.0M-15.3%	$2.4M-3.4%	$2.4M-16.3%	$2.9M-17.5%	$3.5M+55.1%	$2.3M-18.8%	$2.8M-7.5%	$3.0M
Current Liabilities	$1.9M-11.9%	$2.1M+1.0%	$2.1M-11.6%	$2.4M-20.4%	$3.0M+81.5%	$1.7M-20.7%	$2.1M-6.0%	$2.2M
Total Equity	$20.7M-13.0%	$23.7M-12.5%	$27.1M-7.9%	$29.4M-10.9%	$33.1M-13.7%	$38.3M-9.1%	$42.2M-11.0%	$47.4M
Retained Earnings	-$178.8M-2.1%	-$175.2M-2.2%	-$171.3M-2.2%	-$167.6M-2.8%	-$163.1M-4.3%	-$156.4M-3.0%	-$151.9M-4.3%	-$145.6M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

NVNO Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NVNO quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$14.6M	-$15.6M+7.5%	-$16.8M+10.7%	-$18.9M-20.7%	-$15.6M-31.8%	-$11.8M-54.3%	-$7.7M-30.2%	-$5.9M+7.2%	-$6.4M-51.2%	-$4.2M
Capital Expenditures	N/A	$5K-86.5%	$37K+12.1%	$33K-71.3%	$115K-68.8%	$368K+104.1%	$180K-50.5%	$364K+2829.4%	$12K+13.6%	$11K
Free Cash Flow	N/A	-$15.6M+7.7%	-$16.9M+10.7%	-$18.9M-20.1%	-$15.7M-28.8%	-$12.2M-55.5%	-$7.9M-25.5%	-$6.3M+1.7%	-$6.4M-51.2%	-$4.2M
Investing Cash Flow	$14.3M	$15.9M+1087.7%	$1.3M+117.0%	-$7.9M+77.2%	-$34.6M-9289.7%	-$368K-104.1%	-$180K+50.5%	-$364K-2829.4%	-$12K-107.5%	$165K
Financing Cash Flow	N/A	$1.0M-92.5%	$13.6M-47.1%	$25.8M	N/A	$57.6M+282.1%	$15.1M+167.4%	$5.6M-37.6%	$9.0M+122.5%	$4.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.5M-9.6%	-$3.2M+6.0%	-$3.4M+21.6%	-$4.4M-18.2%	-$3.7M+7.5%	-$4.0M+21.3%	-$5.1M-19.4%	-$4.3M
Capital Expenditures	N/A	N/A	$0	$0	N/A	N/A	$4K-55.6%	$9K
Free Cash Flow	N/A	N/A	-$3.4M+21.6%	-$4.4M	N/A	N/A	-$5.1M-19.2%	-$4.3M
Investing Cash Flow	$3.7M+32.4%	$2.8M-33.8%	$4.2M+14.5%	$3.7M+29.4%	$2.8M-45.7%	$5.2M+147.0%	-$11.1M-277.7%	$6.2M
Financing Cash Flow	N/A	N/A	$782K	N/A	N/A	N/A	$0-100.0%	$13.6M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NVNO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

NVNO quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%+99.4pp	0.6%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-24566.5%	-4210.5%	-1445.9%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-24406.7%	-6991.5%	-1845.8%
Return on Equity	-71.8%-20.0pp	-51.7%-0.8pp	-50.9%+12.8pp	-63.7%-33.3pp	-30.4%+98.3pp	-128.7%+641.6pp	-770.3%-129.8pp	-640.5%	N/A
Return on Assets	-65.9%-17.3pp	-48.5%-0.2pp	-48.4%+10.9pp	-59.2%-30.6pp	-28.6%+58.0pp	-86.7%+135.4pp	-222.0%+144.4pp	-366.4%-14.7pp	-351.8%
Current Ratio	13.58-7.3x	20.88-13.4x	34.23+8.5x	25.78-9.1x	34.84+31.8x	3.00+2.2x	0.76-1.1x	1.86	N/A
Debt-to-Equity	0.090.0x	0.070.0x	0.050.0x	0.080.0x	0.06-0.4x	0.48-2.0x	2.47+1.7x	0.75	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-20037.4%	-3413.7%	-998.1%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-17.4%-1.2pp	-16.2%	N/A	-15.4%+4.8pp	-20.3%-8.5pp	-11.8%	N/A	-11.9%
Return on Assets	-15.9%-1.1pp	-14.8%	N/A	-14.0%+4.3pp	-18.3%-7.2pp	-11.1%	N/A	-11.2%
Current Ratio	11.70-0.2x	11.89-1.7x	13.58+0.5x	13.12+1.3x	11.81-12.0x	23.77+2.9x	20.88-1.1x	22.01
Debt-to-Equity	0.100.0x	0.100.0x	0.090.0x	0.100.0x	0.110.0x	0.060.0x	0.070.0x	0.06

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Intelligent Bio Solutions Inc INBS

$7.1M

Nexalin Tech NXL

$8.2M

Ainos Inc AIMD

$10.7M

ALLURION TECHNOLOGIES INC ALUR

$10.0M

Beyond Air Inc XAIR

$4.9M

Where Envveno Medical Corporation Ranks

Frequently Asked Questions

Is Envveno Medical Corporation profitable?

No, Envveno Medical Corporation (NVNO) reported a net income of -$19.5M in fiscal year 2025.

What is Envveno Medical Corporation's EBITDA?

Envveno Medical Corporation (NVNO) had EBITDA of -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Envveno Medical Corporation's return on equity (ROE)?

Envveno Medical Corporation (NVNO) has a return on equity of -71.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Envveno Medical Corporation's free cash flow?

Envveno Medical Corporation (NVNO) recorded an outflow of $15.6M in free cash flow during fiscal year 2025. This represents a 7.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Envveno Medical Corporation's operating cash flow?

Envveno Medical Corporation (NVNO) recorded an outflow of $15.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Envveno Medical Corporation's total assets?

Envveno Medical Corporation (NVNO) had $29.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Envveno Medical Corporation's capital expenditures?

Envveno Medical Corporation (NVNO) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Envveno Medical Corporation spend on research and development?

Envveno Medical Corporation (NVNO) invested $10.0M in research and development during fiscal year 2025.

How many shares does Envveno Medical Corporation have outstanding?

Envveno Medical Corporation (NVNO) had 655,521 shares outstanding as of fiscal year 2025.

What is Envveno Medical Corporation's current ratio?

Envveno Medical Corporation (NVNO) had a current ratio of 13.58 as of fiscal year 2025, which is generally considered healthy.

What is Envveno Medical Corporation's debt-to-equity ratio?

Envveno Medical Corporation (NVNO) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Envveno Medical Corporation's return on assets (ROA)?

Envveno Medical Corporation (NVNO) had a return on assets of -65.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Envveno Medical Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Envveno Medical Corporation (NVNO) held $28.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.6M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Envveno Medical Corporation's Piotroski F-Score?

Envveno Medical Corporation (NVNO) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Envveno Medical Corporation's earnings high quality?

Envveno Medical Corporation (NVNO) reported a net loss of $19.5M while operations used $15.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.